A ROS/ultrasound dual-responsive nanocarrier enhances drug penetration for ameliorating metabolic dysfunction-associated steatohepatitis
Source abstract
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH), as a chronic inflammatory liver disease, presents a significant challenge for effective drug delivery due to excess extracellular matrix (ECM). Here, a reactive oxygen species (ROS)/ultrasound (US) dual-responsive nanodrug loaded with resmetirom and perfluorohexane (PFH), termed RP-LipoTK, was developed for treatment of MASH via scavenging ROS and US-promoted deep drug penetration. The ROS-responsive component of RP-LipoTK achieved selective PEG shedding under ROS-enriched environments of MASH liver. This process facilitated the enhanced accumulation of nanodrug within fibrotic liver tissues. Meanwhile, the PEG shedding synergistically scavenged ROS, thereby mitigating oxidative stress in MASH livers. Subsequently, the cavitation effect of PFH under US exposure elicited a rapid release of resmetirom and promoted its deep penetration into the dense ECM of fibrotic MASH liver tissues. Consequently, RP-LipoTK + US effectively delivered resmetirom into MASH hepatocytes and activated the thyroid hormone receptor β (THR-β) signaling pathways, which distinctly alleviated hepatic steatosis, mitigated liver inflammation and improved lipid metabolism in a MASH mouse model. Collectively, the combination of RP-LipoTK and US represented a promising strategy for the effective management of MASH. STATEMENT OF SIGNIFICANCE: Resmetirom, a first-line drug approved by FDA for the treatment of MASH, has demonstrated promising therapeutic potential in disease management. However, the excessive deposition of extracellular matrix (ECM) in fibrotic MASH liver that restricts drug penetration, as well as the limited oral bioavailability of resmetirom, lead to unsatisfactory treatment efficacy. To overcome these challenges, intravenous administration of resmetirom coupled with an optimized drug delivery system was developed for efficient MASH treatment. Herein, we designed a reactive oxygen species (ROS)/ultrasound (US) dual-responsive nanodrug co-loaded with resmetirom and perfluorohexane (PFH). The nanodrug combines ROS scavenging and US-promoted drug penetration to overcome ECM barriers, resulting in efficient drug delivery in MASH liver. Collectively, the nanodrug achieves significant reduction in inflammation, lipid accumulation, and fibrosis in a MASH mouse model, providing a promising strategy for MASH management.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Liver Disease Diagnosis and Treatment · Cardiovascular Disease and Adiposity · Diet, Metabolism, and Disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review10.1097/HEP.0000000000000004 ↗
2. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes10.1002/hep.28431 ↗
3. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis10.1056/NEJMra1503519 ↗
4. Mechanisms of NAFLD development and therapeutic strategies10.1038/s41591-018-0104-9 ↗
5. Nonalcoholic steatohepatitis: a review10.1001/jama.2020.2298 ↗
6. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies10.1038/nrd.2015.3 ↗
7. Nonalcoholic fatty liver disease: current therapies and future perspectives in drug delivery10.1016/j.jconrel.2023.09.040 ↗
8. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)10.1038/s41392-022-01119-3 ↗
9. Microenvironment-induced programmable nanotherapeutics restore mitochondrial dysfunction for the amelioration of non-alcoholic fatty liver disease10.1016/j.actbio.2025.01.019 ↗
10. Opportunities and challenges following approval of resmetirom for MASH liver disease10.1038/s41591-024-02958-z ↗
11. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges10.1016/j.metabol.2024.155835 ↗
12. Resmetirom for treatment of MASH10.1016/j.cell.2024.05.009 ↗
13. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial10.1016/S0140-6736(19)32517-6 ↗
14. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis10.1056/NEJMoa2309000 ↗
15. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems10.1038/s41573-023-00670-0 ↗
16. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers10.1016/j.addr.2011.12.009 ↗
17. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
18. Solubility determination, dissolution properties and solid transformation of resmetirom (form A) in heptane and seven alcohols10.1039/D3RA02521G ↗
19. Screening, packing systematics, hansen solubility parameters and desolvation of resmetirom (MGL-3196) solvates
20. NPs loaded with zoledronic acid as an advanced tool for cancer therapy
21. Novel pH-responsive hybrid hydrogels for controlled delivery of curcumin: overcoming conventional constraints and enhancing cytotoxicity in MCF-7 cells10.1016/j.hybadv.2024.100210 ↗
22. Exploring the biomedical potential of iron vanadate nanoparticles: a comprehensive review10.1016/j.inoche.2023.111423 ↗
23. PEG-modified Fe2O3 coated agarose hydrogel: a synthesized nanocomposite for regulated 5-fluorouracil delivery10.1016/j.ijbiomac.2024.133900 ↗
24. Triggering and resolution of inflammation in NASH10.1038/s41575-018-0009-6 ↗
25. Hepatic inflammatory responses in liver fibrosis10.1038/s41575-023-00807-x ↗
26. Restoration of sinusoid fenestrae followed by targeted nanoassembly delivery of an anti-fibrotic agent improves treatment efficacy in liver fibrosis
27. A mechanistic study of ultrasonically-enhanced transdermal drug delivery10.1002/jps.2600840607 ↗
28. Ultrasound-mediated intra-/extracellular dual intervening effect combined with all-trans retinoic acid for cancer stemness inhibition10.1016/j.nantod.2024.102207 ↗
29. Ultrasound activated nanobowls with deep penetration for enhancing sonodynamic therapy of orthotopic liver cancer10.1002/advs.202306301 ↗
30. From anatomy to functional and molecular biomarker imaging and therapy: ultrasound is safe, ultrafast, portable, and inexpensive10.1097/RLI.0000000000000675 ↗
31. Ultrasound-responsive theranostic platform for the timely monitoring and efficient thrombolysis in thrombi of tPA resistance10.1038/s41467-024-50741-y ↗
32. Size-modulable nanoprobe for high-performance ultrasound imaging and drug delivery against cancer10.1021/acsnano.8b00076 ↗
33. Sono-promoted drug penetration and extracellular matrix modulation potentiate sonodynamic therapy of pancreatic ductal adenocarcinoma10.1016/j.actbio.2023.02.038 ↗
34. A shielded cascade of targeted nanocarriers spanning multiple microenvironmental barriers for inflammatory disease therapy10.1186/s12951-024-03075-2 ↗
35. ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling10.1186/s12951-022-01435-4 ↗
36. Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD10.1039/D0FO02736G ↗
37. Extracellular vesicles from organoid-derived human retinal progenitor cells prevent lipid overload-induced retinal pigment epithelium injury by regulating fatty acid metabolism10.1002/jev2.12401 ↗
38. BNC1 deficiency-triggered ferroptosis through the NF2-YAP pathway induces primary ovarian insufficiency10.1038/s41467-022-33323-8 ↗
39. 19F MRI/CEUS dual imaging-guided sonodynamic therapy enhances immune checkpoint blockade in triple-negative breast cancer10.1002/advs.202401182 ↗
40. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury10.7150/thno.40395 ↗
41. Thioether phosphatidylcholine liposomes: a novel ROS-responsive platform for drug delivery10.1021/acsami.9b08901 ↗
42. Perfluorohexane-encapsulated mesoporous silica nanocapsules as enhancement agents for highly efficient high intensity focused ultrasound (HIFU)10.1002/adma.201104033 ↗
43. Multiplex ultrasound imaging of perfluorocarbon nanodroplets enabled by decomposition of postvaporization dynamics10.1021/acs.nanolett.3c03719 ↗
44. ATG14 plays a critical role in hepatic lipid droplet homeostasis10.1016/j.metabol.2023.155693 ↗
45. Nile red: a selective fluorescent stain for intracellular lipid droplets10.1083/jcb.100.3.965 ↗
46. Discovery of highly potent and selective thyroid hormone receptor β agonists for the treatment of nonalcoholic steatohepatitis10.1021/acs.jmedchem.2c01669 ↗
47. TG68, a novel thyroid hormone receptor-β agonist for the treatment of NAFLD10.3390/ijms222313105 ↗
48. Longitudinal magnetic resonance imaging with ROS-responsive bilirubin nanoparticles enables monitoring of nonalcoholic steatohepatitis progression to cirrhosis10.1002/adma.202305830 ↗
49. Through-skull fluorescence imaging of the brain in a new near-infrared window10.1038/nphoton.2014.166 ↗
50. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease10.1038/nprot.2013.055 ↗
51. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis10.1016/j.metabol.2015.11.008 ↗
52. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis10.1016/j.addr.2021.113869 ↗
53. Metabolic dysfunction-associated steatohepatitis treated by poly(ethylene glycol)-block-poly(cysteine) block copolymer-based self-assembling antioxidant nanoparticles10.1016/j.jconrel.2024.04.050 ↗
54. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis10.1186/1476-5926-4-10 ↗
55. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise10.1038/s41575-018-0014-9 ↗
56. Plasma metabolomic profile in nonalcoholic fatty liver disease10.1016/j.metabol.2010.03.006 ↗
57. Thyroid hormone receptors: multiple forms, multiple possibilities